Analysts Set TransMedics Group, Inc. (NASDAQ:TMDX) PT at $122.70

Shares of TransMedics Group, Inc. (NASDAQ:TMDX) have received a consensus rating of “Moderate Buy” from the eleven brokerages that are presently covering the firm, MarketBeat.com reports. Three investment analysts have rated the stock with a hold recommendation, seven have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $122.70.

A number of equities analysts have recently weighed in on TMDX shares. Canaccord Genuity Group lowered their target price on TransMedics Group from $109.00 to $104.00 and set a “buy” rating on the stock in a research note on Wednesday, November 20th. Robert W. Baird dropped their target price on TransMedics Group from $150.00 to $120.00 and set an “outperform” rating for the company in a report on Wednesday, December 11th. Baird R W upgraded shares of TransMedics Group to a “strong-buy” rating in a research note on Tuesday, September 24th. Piper Sandler dropped their price objective on shares of TransMedics Group from $110.00 to $90.00 and set an “overweight” rating for the company in a research note on Wednesday, December 11th. Finally, Oppenheimer restated an “outperform” rating and set a $125.00 target price on shares of TransMedics Group in a research report on Tuesday, December 3rd.

TransMedics Group Trading Down 2.5 %

TMDX stock opened at $61.02 on Tuesday. TransMedics Group has a one year low of $59.72 and a one year high of $177.37. The stock has a market cap of $2.05 billion, a price-to-earnings ratio of 64.92 and a beta of 2.06. The company has a fifty day moving average price of $81.71 and a two-hundred day moving average price of $126.16. The company has a debt-to-equity ratio of 2.42, a current ratio of 8.20 and a quick ratio of 7.33.

TransMedics Group (NASDAQ:TMDX) last announced its earnings results on Monday, October 28th. The company reported $0.12 EPS for the quarter, missing the consensus estimate of $0.29 by ($0.17). The company had revenue of $108.76 million for the quarter, compared to the consensus estimate of $115.00 million. TransMedics Group had a return on equity of 18.74% and a net margin of 8.14%. The business’s quarterly revenue was up 63.7% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.12) EPS. Equities analysts anticipate that TransMedics Group will post 1 EPS for the current year.

Insider Activity at TransMedics Group

In other TransMedics Group news, CEO Waleed H. Hassanein sold 8,625 shares of TransMedics Group stock in a transaction dated Tuesday, October 15th. The stock was sold at an average price of $132.71, for a total value of $1,144,623.75. Following the transaction, the chief executive officer now owns 61,643 shares in the company, valued at $8,180,642.53. The trade was a 12.27 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Tamer I. Khayal sold 1,084 shares of the stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $86.40, for a total transaction of $93,657.60. Following the completion of the transaction, the insider now directly owns 20,843 shares of the company’s stock, valued at $1,800,835.20. This trade represents a 4.94 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 19,417 shares of company stock valued at $2,240,738 over the last three months. 7.00% of the stock is owned by insiders.

Institutional Trading of TransMedics Group

Hedge funds and other institutional investors have recently modified their holdings of the stock. Driehaus Capital Management LLC boosted its holdings in shares of TransMedics Group by 15.8% during the 2nd quarter. Driehaus Capital Management LLC now owns 1,486,073 shares of the company’s stock valued at $223,832,000 after acquiring an additional 202,867 shares in the last quarter. Geode Capital Management LLC raised its position in TransMedics Group by 1.3% in the third quarter. Geode Capital Management LLC now owns 763,790 shares of the company’s stock valued at $119,938,000 after purchasing an additional 10,106 shares during the last quarter. Allspring Global Investments Holdings LLC boosted its stake in shares of TransMedics Group by 5.3% during the third quarter. Allspring Global Investments Holdings LLC now owns 599,116 shares of the company’s stock valued at $94,061,000 after purchasing an additional 30,092 shares in the last quarter. Vaughan Nelson Investment Management L.P. grew its holdings in shares of TransMedics Group by 24.3% during the third quarter. Vaughan Nelson Investment Management L.P. now owns 329,010 shares of the company’s stock worth $51,654,000 after purchasing an additional 64,360 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. increased its stake in shares of TransMedics Group by 2.5% in the third quarter. Charles Schwab Investment Management Inc. now owns 271,694 shares of the company’s stock valued at $42,656,000 after buying an additional 6,634 shares during the period. Institutional investors own 99.67% of the company’s stock.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.